Tail Suspension Test: Key Mechanisms and Behavioral Outcomes

The tail suspension test, or TST, is one of the most widely used behavioral assays in neuroscience for screening potential antidepressant drugs and studying depression-related behavior in mice.¹ A mouse is taped by its tail to a small lever or bar, left hanging in the air for six minutes, and researchers measure how long it stays still versus how long it struggles to escape. The logic is deceptively simple: antidepressant drugs make the mouse struggle longer and give up less readily, so immobility becomes a proxy for something like resignation. But the biology behind that behavioral shift involves several interacting brain systems, and the test comes with meaningful limitations that shape how researchers interpret what they see.

How the Test Works in Practice

The TST was introduced in 1985 by Lucien Steru and colleagues as a faster, simpler alternative to the forced swim test for screening antidepressants in mice.² A mouse is suspended by the tail with adhesive tape, positioned so that it cannot grab onto any surface or escape. Over the standard six-minute session, the animal cycles between bouts of active struggling and periods of hanging motionless.¹ The primary measurement is total immobility time. The longer a mouse spends immobile, the more “depressive-like” its behavior is considered. Antidepressant drugs reliably reduce that immobility, and so do psychostimulants, which is one of the complications researchers have to keep in mind.

Because mice sometimes climb their own tails during the test, many labs now thread the tail through a small plastic cylinder before taping it, which physically prevents that climbing behavior. Without this step, the test data can be unreliable, particularly in certain mouse strains. Some labs also measure latency to the first bout of immobility and overall movement energy as secondary indicators of active coping, adding more granularity to what is otherwise a fairly blunt readout.

Serotonin, Norepinephrine, and How Different Drugs Act

The TST’s sensitivity to antidepressants depends heavily on the brain’s monoamine systems, particularly serotonin and norepinephrine. Research using chemical depletion strategies has shown that the two neurotransmitter systems contribute to TST outcomes through partially independent routes. When researchers depleted serotonin from mouse brains, drugs that work by blocking serotonin reuptake (SSRIs like fluoxetine and citalopram) completely lost their ability to reduce immobility in the TST. But depleting serotonin had no effect on drugs that target norepinephrine reuptake instead.³

The norepinephrine side turned out to be more complicated. Blocking catecholamine synthesis alone, or disrupting vesicular storage alone, was not enough to eliminate the effect of norepinephrine-targeting drugs like desipramine. Researchers had to combine both strategies, knocking out both newly made and stored norepinephrine and dopamine, to fully prevent the antidepressant-like response to those drugs.³ This suggests the norepinephrine system has more redundancy built in. Even when one arm of norepinephrine transmission is knocked down, the other can partially compensate, making norepinephrine-targeting drugs harder to fully block in this test.

Age also matters. Juvenile mice (about three weeks old) showed a weaker response to the SSRI escitalopram in the TST compared to older adolescent or adult mice, even though the serotonin transporter itself appeared to mature at the same rate across ages. By contrast, the response to the norepinephrine-targeting drug desipramine was similar at all ages.⁴ The implication is that the brain circuitry downstream of the serotonin transporter, not the transporter itself, is what takes longer to mature. This finding has practical importance for preclinical work modeling pediatric depression, where serotonin-based drugs are already known to behave differently than they do in adults.

Stress Hormones and Brain Growth Factors

Beyond the monoamines, the TST is sensitive to the stress hormone corticosterone, the mouse equivalent of cortisol in humans. Chronically elevated corticosterone produces increased immobility in the TST, mimicking a depressive-like state.⁵ This matters because the stress hormone axis is one of the most consistently implicated systems in human depression. The fact that the TST picks up on it gives the test a layer of biological relevance beyond simple drug screening.

The link between stress hormones and TST behavior runs through brain-derived neurotrophic factor, or BDNF, a protein critical for the survival and growth of neurons, especially in the hippocampus. Chronic corticosterone exposure reduces BDNF levels in the hippocampal dentate gyrus, shrinks the population of new neurons being born there, and disrupts the survival and migration of those that do form.⁶ Treatments that reverse this damage, restoring BDNF signaling and hippocampal neurogenesis, tend to also reverse the increase in TST immobility. For instance, the compound ginsenoside Rg1 was shown to upregulate BDNF pathways, bring corticosterone levels back down, and restore both dendritic spine density and new neuron production in the hippocampus, all while reducing immobility in stressed mice.⁷

This paints a picture where the TST captures, at least in part, the behavioral downstream effects of hippocampal damage caused by chronic stress. The mouse is not literally depressed, but the neural machinery disrupted by prolonged stress hormones overlaps meaningfully with systems implicated in human mood disorders.

What Ketamine Reveals About Fast-Acting Mechanisms

The TST has become an important tool for studying rapid-acting antidepressants, particularly ketamine. In a chronic mild stress model, ketamine significantly reduced TST immobility when a glycogen synthase kinase-3 inhibitor did not, despite both compounds being proposed to share some downstream targets.⁸ This kind of dissociation helps researchers narrow down which specific molecular events actually drive the antidepressant effect versus which are bystander phenomena.

More recent work has zeroed in on a specific receptor type involved. Ketamine reduced TST immobility in both male and female mice, and blocking a particular class of glutamate receptor (calcium-permeable AMPA receptors) reversed ketamine’s behavioral effect entirely without changing immobility on its own.⁹ Female mice needed only half the dose that males required for the same antidepressant-like response, but the mechanism was the same in both sexes. This is the kind of finding where the TST earns its keep: it provides a fast, quantifiable behavioral readout that can be paired with precise pharmacological or genetic manipulations to trace a drug’s mechanism step by step.

Both the R and S forms of ketamine have been tested head-to-head in the TST, with both reducing immobility in stressed mice even a full day after injection.¹⁰ That duration is noteworthy because most conventional antidepressants produce TST effects only while actively present in the brain. The persistent behavioral shift after a single ketamine dose points to lasting changes in synaptic plasticity rather than just temporary neurotransmitter manipulation.

Why Genetics Change Everything

One of the most striking features of the TST is how drastically results vary depending on which strain of mouse you use. Inbred strains show widely differing baseline immobility levels, and genetic mapping has identified several chromosomal regions influencing those differences.¹¹ A study of eleven inbred strains found that genetics accounted for about 31% of the variation in baseline immobility and a striking 60% of the variation in response to the antidepressant imipramine.¹² Whole-genome scans have mapped significant regions on mouse chromosomes 5, 12, and 18 that influence baseline TST behavior.¹³

This genetic sensitivity has a practical upshot and a practical headache. On the positive side, it means the TST can be used to model genetic vulnerability to depression and genetic differences in drug response, which mirrors the real clinical situation where antidepressants work well for some people and not at all for others. The headache is that results from one strain do not automatically generalize to another. A drug that looks promising in DBA/2 mice might fail entirely in C57BL/6 mice, or vice versa, not because the drug does not work but because the background genetics push the behavioral baseline in different directions.

The Tail-Climbing Problem and Other Confounders

The C57BL/6 mouse, one of the most popular research strains in the world, has a particularly awkward relationship with the TST. About 70% of C57BL/6 mice from one major supplier climbed their own tails during the six-minute test, and roughly 35% from another supplier did the same.¹⁴ Other strains showed much lower rates. Tail climbing throws off immobility scoring because the mouse is not immobile but is not engaged in the kind of escape-directed struggling the test is designed to capture either. The plastic cylinder mentioned earlier addresses this, but labs that skip it risk corrupted data.

Opioid drugs create a different confound. Some opioids produce a distinctive curling behavior in the TST that could be mistaken for reduced immobility and scored as an antidepressant-like effect. However, detailed pharmacological work has argued that this curling behavior is distinct from both spontaneous motor activity and the so-called Straub tail effect (a rigid dorsiflexion caused by high-dose opiates). Genetic blockade of a specific opioid receptor decreased curling without changing immobility, suggesting the two behaviors are governed by separate mechanisms.¹⁵ Researchers still need to be careful, though, because any drug that globally increases motor activity could artificially reduce immobility scores without having any real antidepressant effect.

Sex Differences and the Role of Hormones

Female mice do not behave identically to males in the TST, and where they are in their estrous cycle can shift results. In BALB/cByJ mice, TST performance varied significantly depending on the cycle phase. Even in C57BL/6 females, whose behavior was generally more stable across the cycle in other tests, TST performance was the exception and fluctuated with hormonal state.¹⁶

These hormonal effects are not just noise in the data. Leptin, a hormone produced by fat tissue, produced antidepressant-like effects in female mice only during the proestrus phase of the cycle, when estrogen levels are high. Removing the ovaries abolished leptin’s behavioral effects entirely, and replacing estrogen restored them. In males, by contrast, removing the testes had no effect on leptin’s antidepressant-like activity.¹⁷ The implication is that certain antidepressant-relevant signaling pathways in the female brain are gated by estrogen in a way that male pathways are not. This is one reason many older TST studies used only male mice: controlling for estrous cycle effects adds cost and complexity. The tradeoff is that female-specific biology gets overlooked, which is a significant gap given that depression is roughly twice as common in women.

How the TST Differs From the Forced Swim Test

The forced swim test, developed by Roger Porsolt a few years before the TST, measures a similar-looking behavior: a mouse or rat placed in a cylinder of water from which it cannot escape eventually stops swimming and floats. Both tests produce immobility, and both respond to antidepressant drugs, but the underlying neurobiology turns out to be different. Direct pharmacological comparisons found that the forced swim test altered dopamine, its metabolite DOPAC, and serotonin concentrations during the session, while the TST produced no measurable changes in any of those neurotransmitters during the same timeframe.¹⁸

This dissociation extends to specific drug challenges. Repeated ketamine treatment increased immobility in the forced swim test but not in the TST, suggesting different pathophysiological pathways underlie immobility in the two tests. Additionally, the forced swim test showed predictive validity for negative symptoms of schizophrenia, while the TST did not.¹⁹ The two tests are not interchangeable, even though they look similar on the surface and are often treated as backup options for each other in research publications. In practice, a drug’s performance in one does not guarantee the same result in the other, which is why rigorous preclinical programs usually run both.

Circadian Timing and Environmental Variables

When during the day a mouse is tested in the TST affects its immobility, and this sensitivity to timing is more than a minor technical footnote. Immobility scores fluctuate across the light-dark cycle, so animals from different experimental groups need to be tested at the same time of day to avoid introducing a systematic bias.²⁰ Prolonged exposure to constant darkness can itself increase immobility, meaning that housing conditions bleed into behavioral outcomes even before any experimental manipulation begins.

Disruption of the circadian clock at a genetic level produces a striking result. Mice with disrupted circadian rhythms in the brain’s master clock spent more time immobile in the TST and also showed increased anxiety-like behavior in other tests.²¹ This connects to a broader clinical observation: sleep and circadian disruption are among the most common features of major depression in humans, and the TST appears to be capturing at least part of that link in a mouse model.

Transgenic Models and Single-Gene Manipulations

The TST serves as a behavioral screen for genetically engineered mice, allowing researchers to ask whether deleting or overexpressing a single gene changes depression-related behavior. But the answer is not always what you’d expect. Mice overexpressing the neuropeptide galanin, for instance, showed completely normal baseline immobility in the TST, and mice lacking the galanin R1 receptor also behaved normally. Even injecting galanin directly into the brain did not alter TST behavior in normal mice.²² Fluoxetine and desipramine still worked normally in these mutant animals, suggesting that the galanin system, despite its role in other aspects of mood regulation, does not gate the behavioral pathway measured by the TST.

This kind of negative result is genuinely informative. It tells researchers which molecular systems the TST can and cannot detect changes in, helping define the boundaries of the test. A gene that clearly affects anxiety or anhedonia in other assays might produce no signal in the TST, not because it is irrelevant to depression but because the TST measures a particular slice of depression-related behavior, primarily passive coping under acute inescapable stress, and not the full spectrum of depressive symptoms.

Questions About What the Test Really Measures

The TST is frequently described as a test for “behavioral despair,” but that phrase carries more interpretive weight than the data strictly support. What the test directly measures is whether a mouse transitions from active movement to passive hanging, and how quickly and completely it does so. Whether that transition represents something psychologically comparable to despair in a human, or is simply a learned energy-conservation strategy, remains genuinely debated. Both the forced swim test and the TST have faced criticism for being inconsistent across labs and for lacking the kind of construct validity that would make their results reliably translatable to clinical depression.

Still, the TST has concrete practical value. It reliably detects drugs that turn out to work as antidepressants in humans, and it does so cheaply and quickly, which matters when pharmaceutical screening involves testing hundreds of compounds. Its sensitivity to monoamine manipulation, stress hormone levels, BDNF signaling, glutamate receptor activity, genetic background, sex hormones, and circadian disruption means it captures inputs from most of the biological systems currently implicated in human depression, even if the behavioral readout is a crude summary of those inputs. Researchers who use it well tend to pair it with other tests and biological measurements, treating immobility not as a diagnosis of mouse depression but as one data point in a larger picture of how a drug or genetic change affects the brain’s stress response.